Cancer Model Development Centers

Cancer Model Development Centers 

The Cancer Model Development Centers (CMDCs) are the NCI-funded contributors to the HCMI. They are tasked with producing next-generation cancer models from clinical samples. The cancer models will encompass tumor types that are rare, originate from patients from underrepresented populations, or lack precision therapy. These models will be annotated with clinical and genomic data and will become community resource.

  • Broad Institute of Harvard and MIT (BROD): The BROD CMDC co-Directors are Dr. Jesse S. Boehm and Dr. Keith L. Ligon.
  • Cold Spring Harbor Laboratory (CSHL): The Principal Investigator for the CSHL CMDC is Dr. David A. Tuveson.

Associated Clinical and Sequence Data

At the NCI-funded CMDCs, normal tissue, originating tumor, and the derived models* will be sequenced by the Genome Characterization Centers using the following approaches:

  • Whole Genome Sequencing (15X): Supplies data that, when analyzed, provides the DNA sequence of the entire genome.
  • Whole Exome Sequencing (150X): Supplies data that, when analyzed, provides the DNA sequence of almost all of the known protein-coding regions of the genome (exome). Analysis of the data identifies somatic alterations, including indels and single point mutations.
  • Transcriptome Sequencing (RNA-seq): Supplies data that, when analyzed, provides the RNA sequence from protein coding regions. Analysis of the data identifies mutations in the protein-coding regions of the genome and a variety of alterations, including novel gene fusions, and alternatively spliced isoforms.

*150X whole exome sequencing will be performed on a subset of the models after they have been expanded for distribution. The resulting mutational profile will be compared to the one performed at the time of model deposition.

Models will also be annotated with clinical data. Once generated, sequence and clinical data from US-derived models will be available through the Genomic Data Commons.

All data will be made available in a way that protects patient privacy.

 

Last updated: November 03, 2017